NCT05532735 — "Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion" trial site landscape

Public-registry site landscape for NCT05532735, “Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion”, a Retinal Vein Occlusion study sponsored by Annexin Pharmaceuticals AB. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT05532735 (registry record)
Study title	Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
Official title	Open-label, Dose Ascending Safety, Tolerability, and Proof of Concept Study to Evaluate the Use of ANXV (Human Recombinant Annexin A5) in the Treatment of Subjects With Recently Diagnosed Retinal Vein Occlusion
Sponsor	Annexin Pharmaceuticals AB
Condition(s)	Retinal Vein Occlusion
Phase	PHASE2
Listed sites	7
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT05532735.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT05532735 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →